ibi318
mAbexperimentalMulti-specific
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 19, 2019 (NCT03875157)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04777084 | Phase 2 | Mar 1, 2021 | Central South University |
| NCT04672928 | Phase 1 | Dec 21, 2020 | Chinese Academy of Medical Sciences, Innovent Biologics (Suzhou) Co. Ltd., Jilin Provincial Tumor Hospital |
| NCT04611321 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04635527 | Phase 1 | Nov 26, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04602065 | Phase 1/Phase 2 (Phase 2) | Nov 24, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT03875157 | Phase 1 | Apr 19, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 5 | 5 | 2 | 2019 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Jilin Provincial Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1